MedCity News

OCTOBER 11, 2022

It is Mark Cuban Cost Plus Drug Company’s first collaboration with a health plan. The pharmacy company will not be replacing Capital Blue Cross’ existing pharmacy benefits manger, but instead will be an additional option for members to choose.

Prescription 306

Prescription 306

pharmaphorum

JANUARY 6, 2023

In 2023, expect manufacturers to further shift their focus away from acquiring new patient prescriptions to retaining existing customers. The account carried an official blue check mark, but in fact it did not belong to the prescription drugmaker. in 1979 to 2.8%in Ensuring patient access.

Prescription 106

Prescription Manufacturing Patients Side effects 106

Fierce Pharma

JULY 21, 2023

In this episode of 'The Top Line' we replay an important show from April 28, 2023 regarding Narcan. | This week on "The Top Line," we revisit an episode on Narcan the nasal spray. It is the first naloxone product to be approved for use without a prescription.

Specialization 160

Specialization Prescription 160

MedCity News

JUNE 12, 2023

Bringing the very first prescription digital therapeutic (PDT) to market in 2017, Pear Therapeutics went above and beyond to follow suggested regulatory guidelines, obtained Food & Drug Administration (FDA) clearance, and provided solid clinical study evidence. Photo: Bulat Silvia, Getty Images

Food and Drug Administration 263

Food and Drug Administration Prescription Government FDA 263

pharmaphorum

DECEMBER 23, 2022

And in 2023, these investments will hopefully pay off. In 2023, omnichannel behaviours will directly influence incentive compensation models by correlating successful engagement data to successful sales outcomes. Food and Drug Administration’s Office of Prescription Drug Promotion ( OPDP ).”.

Marketing 106

Marketing Sales Medical Patients 106

MedCity News

AUGUST 1, 2023

in 2023, according to CMS. The average total monthly premium for Medicare Part D coverage is expected to be $55.50 in 2024, down from $56.49

Prescription 246

Prescription 246

pharmaphorum

JULY 11, 2024

The US Senate has come together to pass a bill that aims to prevent pharma companies from filing multiple patents around biologic drugs as a way to delay biosimilar competitors.Lawmakers unanimously passed the Affordable Prescriptions for Patients Act of 2023 (S-150), which is part of a lengthening list of measures being taken by Congress to curb the (..)

Prescription 122

Prescription Medicine Pharma Patients 122

PM360

SEPTEMBER 21, 2023

Jeff Casberg, MS, RPh, Senior Vice President of Clinical Pharmacy at IPD Analytics, a managed care and pharmaceutical consultancy, highlighted a wide range of 2023 key events that will affect managed care professionals by the end of the year. This product is expected to have three generic launches in 2023.

Management 105

Management Manufacturing Sales Competition 105

InCrowd

AUGUST 17, 2023

Prescriber Perspectives on Weight Loss Drugs in 2023 Examine how healthcare professionals (HCPs) view and prescribe weight loss drugs currently on the market in our new Instant Insights report.

Prescription 130

Prescription Physicians Management Healthcare 130

World of DTC Marketing

MARCH 10, 2022

The cost of Humira, which is injected via syringe, was more than $72,000 a year on prescription drug websites this week and is not expected to come down until at least 2023. The increase followed total Humira price hikes of 19 percent during 2017 and 2018. The executives at AbbVie make over $300 million.

Prescription 205

Prescription Pharmaceutical products Pharmaceutical Marketing 205

pharmaphorum

DECEMBER 22, 2022

As this collective body of experience continues to proliferate, 2023 will see additional FDA guidance. In 2023, expect to see AI innovations improve enrolment agility and, most importantly, the patient experience in a clinical trial. Beyond 2023 – the Sovereign Patient ID.

FDA 97

FDA Patients Electronics Medical 97

PharmExec

NOVEMBER 7, 2023

Exagamglogene autotemcel (Exa-Cel) was assigned a Prescription Drug User Fee Act action date of December 8, 2023, for the treatment of sickle cell disease.

Prescription 98

Prescription Pharmaceutical 98

PM360

MAY 15, 2023

She combines business problem-solving with a tremendously human-centered approach to their desired outcomes, examining a brand’s specific ability to impact access and speed along the patient prescription journey.” Laura is not shy about sharing her cancer experience.

Sales 94

Sales Pharma sales reps Prescription Recruitment 94

Nixon Gwilt Law

FEBRUARY 27, 2023

Late Friday (February 24, 2023), the US Drug Enforcement Agency (DEA) released a proposed rule to make permanent some of the flexibilities allowed during the Public Health Emergency (PHE) for telemedicine companies whose providers prescribe controlled substances. Now let’s get to it.

Prescription 105

Prescription Medical Patients Specialization 105

European Pharmaceutical Review

MARCH 18, 2025

Novo Nordisk has regained full membership with the Association of the British Pharmaceutical Industry (ABPI), following suspension in 2023. The Prescription Medicines Code of Practice Authority (PMCPA) conducted an in-depth investigation into the case , and requested a further audit from Novo Nordisk.

Pharmaceutical 59

Pharmaceutical Prescription Government Medicine 59

Pharmacy Times

JULY 28, 2023

Thousands more people filled their insulin prescriptions following the introduction of the cap in January 2023, especially compared to those who were not enrolled in Medicare, a new study finds.

Prescription 48

Prescription 48

Pharmaceutical Technology

DECEMBER 4, 2022

Indeed, Amgen’s biosimilar was approved in September 2016, but the company was not able to launch it until January 2023 in the US. In September 2017, Amgen announced that it reached a global settlement with AbbVie, scheduling Amjevita’s American launch for January 31, 2023. Humira biosimilars became available in the EU in October 2018.

Marketing 104

Marketing Physicians Competition Patients 104

PM360

JULY 13, 2023

What if the industry were to incentivize persistence over new prescriptions? NRx data drives stock prices, determines ROI, and directs bonuses. What if instead of short-term gains, we prioritized the long game? Imagine if we collectively proclaimed that the real value is not only in starting, but in staying.

Medical 98

Medical Patients Education Transportation 98

PM360

APRIL 7, 2023

This is especially significant for manufacturers of high-cost specialty drugs, who will now face a recurring additional 20% charge on virtually every prescription fill. On the other side, drug manufacturers are facing the squeeze, with caps on price inflation and a mandated 20% discount in the catastrophic phase.

Manufacturing 97

Manufacturing Insurance Marketing Government 97

Pharma Marketing Network

OCTOBER 26, 2022

Join Reuters Events’ exclusive panel discussion to hear experts from Novartis, Takeda and Janssen share business-critical learnings, including: Differentiate predictive vs prescriptive insights and inform your next best action. The post Pharma USA 2023 | March 28–29, 2023 appeared first on Pharma Marketing Network.

Pharma 52

Pharma Prescription Marketing Networking 52

PM360

NOVEMBER 12, 2023

Technological innovations and changes in consumer behavior over the past 10 years have reduced friction, saved time, and opened new options for consumers and patients seeking routine prescriptions and refills via telehealth. Let’s face it, most consumers seek convenience wherever they can find it.

Prescription 52

Prescription Media Pharma Patients 52

PM360

DECEMBER 14, 2023

Survey any physician if they’ve been asked by a patient about a prescription weight loss medication and you’ll hear a resounding “yes.” The recent Sermo Barometer confirms that 89% of 300+ global practitioners have seen an increase in patients proactively requesting prescription weight loss medications.

Medical 105

Medical Side effects Physicians Prescription 105

MedReps

JANUARY 30, 2023

Medical Sales Trends to Watch Out For in 2023 If you want to know what the future holds and create some forward-thinking sales goals, then check out these medical sales trends to watch out for in 2023. Along with an increase in elderly people, there’s also more healthcare spending taking place.

Medical sales 74

Medical sales Medical Sales Sales goal 74

European Pharmaceutical Review

OCTOBER 24, 2023

Contributing factors include greater demand for prescription drugs , advancements in the designing and printing of labels, high investments as well as pharmaceutical sales, plus high research and development (R&D) expenditures on pharmaceuticals and government initiatives. percent between the forecast period: 2023 and 2028.

Pharmaceutical 118

Pharmaceutical Marketing Medicine Pharmaceutical Sales 118

Pharmaceutical Technology

MAY 25, 2023

The US Food and Drug Administration has set 23 September 2023 as the prescription drug user fee action date for ATI-1501.

Food and Drug Administration 105

Food and Drug Administration Prescription Food Marketing 105

PharmExec

APRIL 14, 2023

Using prescription digital therapeutics can lead to better outcomes for patients, making them a win-win for pharma and patients.

Pharma 52

Pharma Prescription Leads Patients 52

Pharmaceutical Technology

MAY 26, 2023

The FDA has now assigned a prescription drug user fee act action date of 23 November 2023 for the NDA.

Food and Drug Administration 105

Food and Drug Administration FDA Prescription Food 105

PharmExec

JANUARY 29, 2025

Prescription data between 2017 and 2023 revealed that while Adderall prescription fills decreased following the shortage, many children transitioned to alternative stimulants for attention-deficit/hyperactivity disorder.

Prescription 52

Prescription Medical 52

Pharmaceutical Commerce

NOVEMBER 10, 2023

Blue Fin Group exec speaks on his upcoming feature.

Prescription 52

Prescription 52

Pharmaceutical Technology

JANUARY 16, 2023

Untamed inflation is a top concern for the pharmaceutical industry globally in 2023. The legislation contains several provisions to lower prescription drug costs, including allowing Medicare to negotiate the cost of selected medicines. Negotiations over these products are expected from October 2023 and run until August 2024.

Pharma 64

Pharma Pharmaceutical Manufacturing Marketing 64

PM360

MAY 15, 2023

Karina joined OptimizeRx in 2021, where she has increased the digitalization of access to help move drug manufacturers away from manual processes.

Physicians 59

Physicians Electronics Manufacturing Prescription 59

Eversana Intouch

JANUARY 19, 2023

Success in 2023 will mean addressing each of those five issues meaningfully – understanding them fully and giving them real action, not just lip service. Pharma marketers in 2023 need to: Look for blind spots. Each year, we forecast several trends that will influence life-sciences marketing the most in the months to come ahead.

Medical 52

Medical Education Competition Marketing 52

Pharmaceutical Technology

MAY 2, 2023

The regulatory body has also granted priority review to the application and set 28 August 2023 as a target date for the prescription drug user fee act (PDUFA). The European Medicines Agency (EMA) has also validated the Type II variation application for Reblozyl.

Food and Drug Administration 98

Food and Drug Administration FDA Safety Prescription 98

PM360

JANUARY 24, 2025

Advertisers want to engage audiences, but at the same time, need to adhere to updated FDA guidance released in November of 2023 for pharmaceutical ads. This guidance emphasizes clear presentation of risk information and ensures that, among other criteria, music in ads is not a distraction.

Side effects 52

Side effects Media Networking FDA 52

PM360

NOVEMBER 21, 2024

In Korlym’s 12th year on the market, the team was able to maximize the revised positioning, new campaigns, and new educational initiatives to increase new prescription demand by almost 50% and revenue by 39% (Q2 2024 vs. Q2 2023).*

Marketing 52

Marketing Education Prescription Sales 52

European Pharmaceutical Review

APRIL 13, 2023

Psychedelic research: evaluating the fast-evolving regulatory roadmap Psychedelics: the position in Europe The EMA’s recent letter confirms that as of 17 February 2023 in the EU, 6 there were: 11 ongoing clinical trials in EU with psilocybin for a range of central nervous system conditions four ongoing trials with MDMA one trial with LSD.

Medicine 131

Medicine Food and Drug Administration Doctors Medical 131

Pharmaceutical Technology

JUNE 20, 2023

The US FDA has assigned 26 October 2023 as the Prescription Drug User Fee Act (PDUFA) date for its decision. The company intends to commercialise vamorolone in key European locations, including the UK, Italy, Germany, France, Spain and the Benelux countries.

Food and Drug Administration 98

Food and Drug Administration FDA Prescription Medicine 98